Tasosartan

Tasosartan is an angiotensin II receptor antagonist.

Tasosartan
Clinical data

Pregnancy category	N/A
ATC code	C09CA05 (WHO)
Legal status
Legal status	Withdrawn
Identifiers
IUPAC name 2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
CAS Number	145733-36-4^Y
PubChem CID	60919
IUPHAR/BPS	6898
DrugBank	DB01349^Y
ChemSpider	54890^N
UNII	48G92V856H
CompTox Dashboard (EPA)	DTXSID40163148
Chemical and physical data
Formula	C₂₃H₂₁N₇O
Molar mass	411.469 g·mol⁻¹
^NY (what is this?) (verify)

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]

References

Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 978-0-12-369417-1.
Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. doi:10.1093/ajhp/57.13.1231. PMID 10902066.

Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan (+HCT) Losartan (+HCT) Olmesartan (+amlodipine) Tasosartan^§ Telmisartan (+HCT) Valsartan (+HCT, +amlodipine)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Angiotensin receptor modulators
ATR	Agonists: Angiotensin II Angiotensin III Angiotensin IV L-163,491 Saralasin Antagonists: Abitesartan Azilsartan Candesartan Elisartan Embusartan Eprosartan EXP-3174 Fimasartan Forasartan Irbesartan Losartan Milfasartan Olmesartan Olodanrigan PD123319 Pomisartan Pratosartan Ripisartan Saprisartan Sparsentan Tasosartan Telmisartan Valsartan Zolasartan ACE inhibitors: Alacepril Benazepril Captopril Cilazapril Delapril Enalapril Enalaprilat Fosinopril Gemopatrilat Imidapril Lisinopril Moexipril Omapatrilat Perindopril Quinapril Quinaprilat Ramipril Rentiapril Rescinnamine Spirapril Spiraprilat Temocapril Trandolapril Zofenopril Zofenoprilat Renin inhibitors: Aliskiren Ciprokiren Ditekiren Enalkiren Imarikiren Pepstatin Remikiren Terlakiren Zankiren Propeptides: Angiotensinogen Angiotensin I
Combinations:	Valsartan/hydrochlorothiazide Valsartan/hydrochlorothiazide/amlodipine Amlodipine/valsartan
See also Receptor/signaling modulators Signaling peptide/protein receptor modulators

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.